Quick Takeaways
- IDEXX Laboratories has expanded its Fecal Dx antigen testing platform to include detection of taeniid tapeworms, including Taenia and Echinococcus species, further broadening intestinal parasite screening capabilities for companion animals. The enhanced test is designed to detect infections earlier and more comprehensively than fecal flotation alone, supporting both wellness and sick-pet diagnostics.
- Since its launch in 2012, more than 50Mn Fecal Dx antigen tests have been performed globally, with the platform evolving into a scalable diagnostic solution for veterinary practices. With the latest addition, Fecal Dx now detects seven major intestinal parasite groups, including hookworm, roundworm, whipworm, flea tapeworm, taeniid tapeworm, Cystoisospora, and Giardia in select panels.
- The inclusion of Taenia and Echinococcus species addresses growing veterinary and zoonotic concerns, particularly in endemic regions across Europe, the US, and Canada where Echinococcus infections remain clinically significant. IDEXX confirmed that beginning in late June, taeniid tapeworm detection will be automatically incorporated into Fecal Dx antigen testing panels and profiles for IDEXX Reference Laboratories customers in the US and Canada at no additional cost.
Why It Matters?
IDEXX is turning Fecal Dx into an even more comprehensive intestinal parasite screen while quietly increasing its value proposition to vets without raising prices.
Adding taeniid tapeworms (Taenia and Echinococcus) strengthens the platform’s role in both pet health and zoonotic risk management, especially in endemic areas in North America and Europe.
Automatically bundling this capability into existing Fecal Dx panels at no additional cost from late June should drive further migration from basic fecal flotation to antigen testing, deepen IDEXX’s integration into clinic workflows, and support recurring reference-lab revenue.
Source: Businesswire
